COVID-19 STAndard of Care in Sub-Saharan Africa

Covid19 Clinical Trial

— COVISTA  

Official title:

Observational Study of the Clinico-biological Evolution and the Standard of Care Offered to Symptomatic Covid-19 Patients in Sub-Saharan Africa

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04885543
• Other study ID #: ALIMA02
• Status: Completed
• Start date: March 1, 2020
• Est. completion date: March 1, 2021

Study information

• Verified date: May 2021
• Source: Alliance for International Medical Action
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study was conducted in three African countries on four COVID-19 care centers (CCCs). The CCCs were set up in collaboration with a medical NGO with long experience in recording and monitoring data for cohorts and clinical trials in emergency contexts. The data were recorded using the WHO COVID-19 rapid core case report form.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2495
• Est. completion date: March 1, 2021
• Est. primary completion date: March 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• SARS-CoV-2 positive at RT-PCR

Exclusion Criteria:

• Asymptomatic patients

Related Conditions & MeSH terms

• Covid19

Locations

Country	Name	City	State
Burkina Faso	Chu Tengandogo	Ouagadougou
Burkina Faso	Clinique Princesse Sarah	Ouagadougou
Guinea	Chu Donka	Conakry

Sponsors (1)

Lead Sponsor	Collaborator
Alliance for International Medical Action

Countries where clinical trial is conducted

Burkina Faso,  Guinea, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mortality	In hospital mortality	During hospitalization, with an average of 11 days
Secondary	Clinical worsening	Combination of an SpO2 <94% at least once during follow-up (including at baseline), use of oxygen therapy at any time during follow-up, or death	Hospitalization, with an average of 11 days